AmerisourceBergen Corporation (ABG) - Net Assets
Based on the latest financial reports, AmerisourceBergen Corporation (ABG) has net assets worth €2.10 Billion EUR as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€78.36 Billion) and total liabilities (€76.27 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.10 Billion |
| % of Total Assets | 2.67% |
| Annual Growth Rate | -8.58% |
| 5-Year Change | 198.95% |
| 10-Year Change | N/A |
| Growth Volatility | 352.43 |
AmerisourceBergen Corporation - Net Assets Trend (2019–2025)
This chart illustrates how AmerisourceBergen Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AmerisourceBergen Corporation (2019–2025)
The table below shows the annual net assets of AmerisourceBergen Corporation from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | €1.75 Billion | +122.07% |
| 2024-09-30 | €786.74 Million | +18.08% |
| 2023-09-30 | €666.29 Million | +834.84% |
| 2022-09-30 | €71.27 Million | -87.80% |
| 2021-09-30 | €584.41 Million | +169.60% |
| 2020-09-30 | €-839.64 Million | -128.05% |
| 2019-09-30 | €2.99 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to AmerisourceBergen Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 54.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €6.53 Billion | 433.30% |
| Total Equity | €1.51 Billion | 100.00% |
AmerisourceBergen Corporation Competitors by Market Cap
The table below lists competitors of AmerisourceBergen Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AutoZone Inc
NYSE:AZO
|
$59.19 Billion |
|
Baker Hughes Co
NASDAQ:BKR
|
$59.29 Billion |
|
Aflac Incorporated
NYSE:AFL
|
$59.40 Billion |
|
Sempra
SA:S1RE34
|
$59.51 Billion |
|
Lloyds Banking Group plc
F:LLD2
|
$58.81 Billion |
|
Nu Holdings Ltd
NYSE:NU
|
$58.80 Billion |
|
APOLLO GL.M.NEW DL-00001
F:N7I
|
$58.68 Billion |
|
Wesfarmers Ltd
AU:WES
|
$58.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AmerisourceBergen Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 645,938,000 to 1,508,019,000, a change of 862,081,000 (133.5%).
- Net income of 1,554,169,000 contributed positively to equity growth.
- Dividend payments of 437,081,000 reduced retained earnings.
- Share repurchases of 435,471,000 reduced equity.
- Other factors increased equity by 180,464,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €1.55 Billion | +103.06% |
| Dividends Paid | €437.08 Million | -28.98% |
| Share Repurchases | €435.47 Million | -28.88% |
| Other Changes | €180.46 Million | +11.97% |
| Total Change | €- | 133.46% |
Book Value vs Market Value Analysis
This analysis compares AmerisourceBergen Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 35.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 19.06x to 35.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | €14.48 | €275.90 | x |
| 2020-09-30 | €-4.11 | €275.90 | x |
| 2021-09-30 | €1.07 | €275.90 | x |
| 2022-09-30 | €-1.41 | €275.90 | x |
| 2023-09-30 | €2.60 | €275.90 | x |
| 2024-09-30 | €3.31 | €275.90 | x |
| 2025-09-30 | €7.78 | €275.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AmerisourceBergen Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 103.06%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.48%
- • Asset Turnover: 4.20x
- • Equity Multiplier: 50.79x
- Recent ROE (103.06%) is below the historical average (198.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 28.58% | 0.48% | 4.58x | 13.09x | €556.04 Million |
| 2020 | 0.00% | -1.80% | 4.32x | 0.00x | €-3.32 Billion |
| 2021 | 689.46% | 0.72% | 3.73x | 256.71x | €1.52 Billion |
| 2022 | 0.00% | 0.71% | 4.22x | 0.00x | €1.73 Billion |
| 2023 | 334.35% | 0.67% | 4.19x | 119.84x | €1.69 Billion |
| 2024 | 233.63% | 0.51% | 4.38x | 103.88x | €1.44 Billion |
| 2025 | 103.06% | 0.48% | 4.20x | 50.79x | €1.40 Billion |
Industry Comparison
This section compares AmerisourceBergen Corporation's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $366,414,995,410
- Average return on equity (ROE) among peers: 0.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AmerisourceBergen Corporation (ABG) | €2.10 Billion | 28.58% | 36.39x | $59.07 Billion |
| MEDIPAL HOLDINGS CORP. (59Z) | $688.05 Billion | 5.64% | 1.48x | $3.28 Billion |
| GROUPE EUROMEDIS EO 2 (61R) | $16.48 Million | -37.06% | 1.35x | $13.55 Million |
| AKSO HEALTH GR. (SPADR)/3 (8HX) | $138.42 Million | -6.83% | 0.03x | $1.60 Billion |
| Sipai Health Technology Co. Ltd. (AX1) | $1.63 Billion | -15.68% | 0.73x | $135.54 Million |
| Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) | $31.33 Billion | 11.87% | 1.11x | $460.18 Million |
| KIMIA FARMA -B- (HQP) | $2.57 Trillion | 12.70% | 1.37x | $831.52 Million |
| Asker Healthcare Group AB (I88) | $3.50 Billion | 10.28% | 2.75x | $3.15 Billion |
| Medios AG (ILM1) | $514.22 Million | 2.99% | 0.76x | $311.23 Million |
| M1 Kliniken AG (M12) | $30.26 Million | 16.55% | 0.06x | $300.08 Million |
About AmerisourceBergen Corporation
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical cli… Read more